

I. Relevant related publications list, from 2008

Publications from CEEISCAT

Casabona J. [Is it still useful to monitorize HIV prevalence among pregnant women by means of unlinked anonymous screening?]. *Med Clin (Barc)*. 2008;131(7):253-6. Spanish.

Vives N, Almeda J, Contreras C, García F, Campins M, Casabona J; NONOPEP Study Group. [Use of non-occupational HIV post-exposure prophylaxis in Spain (2001-2005)]. *Enferm Infecc Microbiol Clin [Internet]*. 2008 [cited 2008 Jan. 25]; 26(9):546-51. Spanish. Available from: http://www.elsevier.es/revistas/ctl_servlet?_f=7264&articuloId=13128270&revistaid=28

Gonzalez V, Martro E, Folch C, Esteve A, Matas L, Montoliu A, et al. Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. *Eur J Clin Microbiol Infect Dis*. 2008;27(2):121-6.

Jaen A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, et al.; PISCIS Study Group. Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy. PISCIS Cohort (Spain). *J Acquir Immune Defic Syndr*. 2008;47(2):212-20.

The Antiretroviral Therapy (ART) Cohort Collaboration. Does short-term virologic failure translate to clinical events in ARV-naive patients initiating ART in clinical practice? *AIDS [Internet]*. 2008 [cited 2010 Mar. 28];22(18):2481-92. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793403/?tool=pubmed>

Darwich L, Esteve A, Ruiz L, Paredes R, Bellido R, Cabrera C, et al. Drug-re-

sistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions. *AIDS Res Hum Retroviruses*. 2008;24(5):725-32.

Pérez A, Herranz M, Segura M, Padilla E, Gil F, Durán G, et al. Epidemiologic impact of blood culture practices and antibiotic consumption on pneumococcal bacteraemia in children. *Eur J Clin Microbiol Infect Dis*. 2008;27(8):717-24.

Gonzalez-Tome MI, Ramos Amador JT, Guillen S, Solis I, Fernandez-Ibieta M, Munoz E, et al.; Spanish Cohort of HIV-infected Mother-Infant Pairs. Gestational diabetes mellitus in a cohort of HIV-1 infected women. *HIV Med*. 2008;9(10):868-74.

Navarro G, Nogueras MM, Segura F, Casabona J, Miro JM, Murillas J, et al.; PISCIS Study group. HIV-1 infected patients older than 50 years. PISCIS cohort study. *J Infect*. 2008;57(1):64-71.

The Antiretroviral Therapy (ART) Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries. A collaborative analysis of 14 cohort studies. *Lancet*. 2008;372(9635):293-9.

Rey D, Karim Bendiane M, Bouhnik AD, Almeda J, Moatti JP, Carrieri MP. Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV. Results from South-Eastern France. *Aids Care*. 2008;20(5):537-41.

Folch C, Esteve A, Sanclemente C, Martró E, Lugo R, Molinos S, et al. Prevalence of Human Immunodeficiency Virus, Chlamydia trachomatis and Neisseria gonorrhoeae, and

risk factors for Sexually Transmitted Infections among immigrant female sex workers in Catalonia, Spain. *Sex Transm Dis*. 2008;35(2):178-83.

Serra A, Romero R, Lopez D, Navarro M, Esteve A, Perez N, et al. Renal injury in the extremely obese patients with normal renal function. *Kidney Int*. 2008;73(8):947-55.

Porras C, Sabidó M, Fernández-Dávila P, Fernández VH, Batres A, Casabona J. Reproductive health and healthcare among sex workers in Escuintla, Guatemala. *Cult Health Sex*. 2008;10(5):529-38.

The Collaboration of Observation HIV Epidemiological Research Europe (COHERE). Response to combination antiretroviral therapy: variation by age. *AIDS*. 2008;22(12):1463-73.

Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al.; Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. *Antivir Ther*. 2008;13(8):959-67.

Lugo R, López E. Infeccions de transmissió sexual a Catalunya. *Infosida [Internet]*. 2008 [cited 2010 Nov.18];35. Available from: <http://www.gencat.cat/salut/depsalut/pdf/infosida35.pdf>

Folch C. [Monitoring of the prevalence of HIV infection and the sexual behaviours associated with its transmission in men who have sex with men]. *Infosida [Internet]*. 2008 [cited 2010 Nov. 18]; 37. Catalan. Available from: <http://www.gencat.cat/salut/depsalut/html/ca/dir2138/infosida37.pdf>

Sabido M, Hernandez G, Gonzalez V, Vallès X, Montoliu A, Figuerola J, et al. Clinic-based evaluation of a rapid point-of-care test for detection of *Chlamydia trachomatis* in specimens from sex workers in Escuintla, Guatemala. *J Clin Microbiol* [Internet]. 2009 [cited 2010 Mar. 10]; 47(2):475-6. Available from: <http://jcm.asm.org/cgi/content/full/47/2/475?view=long&pmid=19052178>

Ríos E, Ferrer L, Casabona J, Caylá J, Avencilla A, Gómez i Prat J, et al. [Knowledge of HIV and sexually-transmitted diseases in Latin American and Maghrebi immigrants in Catalonia (Spain)]. *Gac Sanit* [Internet]. 2009 [cited 2010 Jan.10];23(6):533-8. Spanish. Available from: http://www.elsevier.es/revistas/ctl_servlet?_f=7264&articuloId=13145413&revistaid=138

Folch C, Sanclemente C, Esteve A, Martro E, Molinos S, Casabona J; HIVITS-TS Study Group. [Social characteristics, risk behaviours and differences in the prevalence of HIV/sexually transmitted infections between Spanish and immigrant female sex workers in Catalonia, Spain]. *Med Clin (Barc)*. 2009;132(10):385-8. Spanish.

Mirandola M, Folch C, Krampac I, Nita I, Stanekova D, Stehlikova D, et al.; the SIALON network. HIV biobehavioural survey among men who have sex with men in Barcelona, Bratislava, Bucharest, Ljubljana, Prague and Verona, 2008-2009. *Euro Surveill* [Internet]. 2009 [cited 2010 Mar. 30];14(48). Available from: <http://www.eurosurveillance.org/images/dynamic/EE/V14N48/art19427.pdf>

Collaboration of Observation HIV Epidemiological Research Europe (COHERE). Incidence and risk factors of HIV-associated non-Hodgkin lymphoma in the era of combination antiretroviral therapy. European multi-cohort study. *Antivir Ther*. 2009;14(8):1065-74.

Valles X, Murga GB, Hernandez G, Sabido M, Chui A, Lloveras B, et al. High Prevalence of human papillomavirus infection in the female population of Guatemala. *Int J Cancer*. 2009; 125(5):1161-7.

Esteve A, Boj E, Fortiana J. Interaction terms in distance-based regression. *Commun Stat Theory Methods*. 2009;38:3498-509.

Antiretroviral Therapy (ART) Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *Int J Epidemiol*. 2009;38:1624-33.

The antiretroviral therapy cohort collaboration (ART-CC). Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS*. 2009;23:2199-208.

Romero A, Gonzalez V, Granell M, Matas L, Esteve A, Martro E, et al. Recently Acquired HIV Infections in Spain (2003-2005). Introduction of the serological testing algorithm for recent HIV seroconversion. *Sex Transm Inf* [Internet]. 2009 [cited 2010 May 6];85(2):106-10. Available from: <http://sti.bmj.com/content/85/2/106.long>

Calmet M, Juve R, Alberny M, Andreu A, Loureiro E, Matas L, et al. [Diagnostic resources for sexually transmitted infections in laboratories in Catalonia (Spain)]. *Gac Sanit* [Internet]. 2009 [cited 2010 Sept. 20];23(4):348-50. Spanish. Available from: http://www.elsevier.es/revistas/ctl_servlet?_f=7264&articuloId=13139932&revistaid=138

Sullivan PS, Hamouda O, Delpuch V, Geduld J, Prejean J, Semaille C, et al.; Annecy MSM Epidemiology Study Group. Reemergence of the HIV epi-

demic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. *Ann Epidemiol*. 2009;19(6): 423-31.

Folch C, Munoz R, Zaragoza K, Casabona J. Sexual risk behaviour and its determinants among men who have sex with men in Catalonia, Spain. *Euro Surveill* [Internet]. 2009 [cited 2010 Mar. 30];14(47):pii=19415. Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19415>

Sabido M, Giardina F, Hernandez G, Fernandez VH, Monzon JE, Ortiz R, et al.; for the UALE team. The UALE Project: decline in the incidence of HIV and Sexually Transmitted Infections and Increase in the use of condoms among Sex Workers in Guatemala. *J Acquir Immune Defic Syndr*. 2009;51(Suppl.1):S35-S41.

The Antiretroviral Therapy (ART) Cohort Collaboration. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1 infected people: a collaborative analysis of 18 HIV cohort studies. *The Lancet*. 2009;373(9672):1352-63.

The Antiretroviral Therapy (ART) Cohort Collaboration. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy. Not all AIDS-defining conditions are created equal. *Clin Infect Dis* [Internet]. 2009 [cited 2009 Oct. 7]; 48(8):1138-51. Available from: http://www.journals.uchicago.edu/doi/abs/10.1086/597468?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov

The Antiretroviral Therapy (ART) Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppres-

sion. *J Acquir Immune Defic Syndr*. 2009;52(3):357-63.

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients startign combination antiretroviral therapy. *AIDS*. 2009;23(15):2029-37.

Folch C. [Drug use and sexual risk behaviour among men who have sex with men]. *Infosida* [Internet]. 2009 [cited 2011 Feb. 3]; 38. Catalan. Available from: <http://www.gencat.cat/salut/depsalut/html/ca/dir2138/infosida38.pdf>

Betancourt A, Ortega N. [Antiretroviral treatment among people living with HIV in Catalonia. PISCIS Cohort 1998-2006]. *Infosida* [Internet]. 2009 [cited 2011 Feb. 3]; 39. Catalan. Available from: <http://www.gencat.cat/salut/depsalut/html/ca/dir2138/index.html>

Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, et al. Triple-class virologic failure in HIV infected patients undergoing antiretroviral therapy for up to 10 years. *Arch Intern Med*. 2010;170(5):410-9.

Marshall V, Martró E, Labo N, Ray A, Wang D, Mbisa G, et al.; EUROSHAKS Study Group. Kaposi Sarcoma (KS)-associated Herpesvirus MicroRNA Sequence Analysis and KS Risk in a European AIDS-KS Case Control Study. *J Infect Dis*. 2010;202(7):1126-35.

Barczyk J, García J, Casabona J. The potential contribution of small-scale intervention projects in the field to the national health information system for HIV and sexually transmitted infections: a case study of a multilevel intervention in Guatemala. *Int J Public Health*. 2010; 55(6):693-9.

Study Group on Death Rates at High CD4 Count in Antiretroviral Naïve Patients. Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. *Lancet*. 2010;376(9738):340-5.

The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS*. 2010;24(1):123-37.

Folch C, Casabona J, Muñoz R, González V, Zaragoza K. [Increase in the prevalence of HIV and in associated risk behaviors in men who have sex with men: 12 years of behavioral surveillance surveys in Catalonia (Spain)]. *Gac Sanit* [Internet]. 2010 [cited 2010 Mar. 10];24:40-6. Spanish. Available from: http://www.elsevier.es/revistas/ctl_servlet?_f=7264&articuloId=13147136&revistaid=138

Folch C, Esteve A, Zaragoza K, Muñoz R, Casabona J. Correlates of intensive alcohol and drug use in men who have sex with men in Catalonia, Spain. *Eur J Public Health*. 2010;20(2):139-45.

The Antiretroviral Therapy Cohort Collaboration. Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996 - 2006: Collaborative Analysis of 13 HIV Cohort Studies. *Clin Infect Dis*. 2010;50(10):1387-96.

Huntington S, Folch C, González V, Merono M, Ncube F, Casabona J. [Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia]. *Enferm Infecc Microbiol Clin* [Internet]. 2010 [cited 2010 May 3];28(4):236-8. Spanish. Available from: http://www.elsevier.es/revistas/ctl_servlet?_f=7264&articuloId=13149866&revistaid=28

Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. *Nat Med*. 2010;16(4):460-5.

Fernandez-Lopez L, Rifa B, Pujol F, Berra J, Perez M, Merono M, et al. Impact of the introduction of rapid HIV testing in the Voluntary Counselling and Testing sites network of Catalonia, Spain. *Int J STD AIDS*. 2010;21(6):288-9.

Martin-Iguacel R, Llibre JM, Nielsen H, Heras E, Matas L, Lugo R, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialized countries. *Eur J Clin Microbiol Infect Dis*. 2010;29(8):917-25.

Corbeto E, Lugo R, Martro E, Falguera G, Ros R, Avecilla A, et al. Epidemiological features and determinants for Chlamydia trachomatis infection among women in Catalonia, Spain. *Int J STD AIDS*. 2010;21(10):718-22.

Other relevant Publications

Belza MJ, de la Fuente L, Suárez M, Vallejo F, García M, López M, et al.; Health And Sexual Behaviour Survey Group. Men who pay for sex in Spain and condom use: prevalence and correlates in a representative sample of the general population. *Sex Transm Infect*. 2008;84(3):207-11.

Vall-Mayans M, Caballero E. [Lymphogranuloma venereum: an emerging cause of proctitis in homosexual men in Barcelona]. *Rev Clin Esp*. 2009;209(2):78-81. Spanish.

Bravo MJ, Royuela L, De la Fuente L, Brugal MT, Barrio G, Domingo-Salvany A; Itinere Project Group. Use of supervised injection facilities and injection risk behaviours among young drug injectors. *Addiction*. 2009;104(4):614-9.

Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, et al. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. *Clin Infect Dis*. 2009;48(10):1467-70.

De la Fuente L, Suarez M, Belza MJ, Vallejo F, García M, Alvarez R, et al. Human immunodeficiency virus testing uptake and risk behaviours in Spain. *J Epidemiol Community Health*. 2009;63(7):552-8.

Castilla J, Guevara M. [Immigration and HIV in Spain]. *Enferm Infecc Microbiol Clin*. 2009;27(7):375-6. Spanish.

Caro-Murillo AM, Gutiérrez F, Manuel Ramos J, Sobrino P, Miró JM, López-Cortés LF, et al. [HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)]. *Enferm Infecc Microbiol Clin*. 2009;27(7):380-8. Spanish.

De la Fuente L, Delgado J, Hoyos J, Belza MJ, Alvarez J, Gutiérrez J, et al.; Madrid Rapid HIV Testing Group. Increasing early diagnosis of HIV through rapid testing in a street outreach program in Spain. *AIDS Patient Care STDS*. 2009;23(8):625-9.

Piñero L, Montes M, Gil-Setas A, Camino X, Echeverría MJ, Cilla G. [Genotyping of *Chlamydia trachomatis* in an area of northern Spain]. *Enferm Infecc Microbiol Clin*. 2009;27(8):462-4. Spanish.

Mothe B, Perez I, Domingo P, Podzamczak D, Ribera E, Curran A, et al. HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. *Curr HIV Res*. 2009;7(6):597-600.

Del Amo J, González C, Belda J, Fernández E, Martínez R, Gómez I, et al. Prevalence and risk factors of highrisk

human papillomavirus in female sex workers in Spain: differences by geographical origin. *J Womens Health (Larchmt)*. 2009;18(12):2057-64.

Yebra G, Holguín A. [Epidemiology of drug-resistant HIV-1 transmission in naïve patients in Spain]. *Med Clin (Barc)*. 2010;135(12):561-7. Spanish.

Brugal MT, Pulido J, Toro C, de la Fuente L, Bravo MJ, Ballesta R, et al. Injecting, sexual risk behaviors and HIV infection in young cocaine and heroin users in Spain. *Eur Addict Res*. 2009;15(3):171-8.

Caro-Murillo AM, Castilla Catalán J, del Amo Valero J. [Epidemiology of HIV infection in immigrants in Spain: information sources, characteristics, magnitude and tendencies]. *Gac Sanit*. 2010;24(1):81-8. Spanish.

Hurtado I, Alastrue I, García de Ollalla P, Albiach D, Martín D, Martín M, et al. [Preventive intervention in venues for interaction used by men who have sex with men]. *Gac Sanit [Internet]*. 2010. [cited 2010 Mar. 10]; 24(1):78-80. Spanish. Available from: http://www.elsevier.es/revistas/ctl_servlet?_f=7064&ip=87.221.208.187&articuloId=13147143&revistaId=138

Caro-Murillo AM, Gil Luciano A, Navarro Rubio G, Leal Noval M, Blanco Ramos JR; los miembros de la Cohorte de la Red de Investigación en Sida (CoRIS). [HIV infection in different age groups: Potential implications for prevention. CoRIS Cohort, Spain, 2004-2008]. *Med Clin (Barc)*. 2010;134:521-7. Spanish.

Del Romero J, Castilla J, Hernando V, Rodríguez C, García S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. *BMJ*. 2010;340:c2205.

Interesting websites

Public Health Agency. Consorci Sanitari de Barcelona
<http://www.aspb.es/>

Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention-
<http://www.cdc.gov/nchhstp/>

Sexually Transmitted Diseases
<http://www.cdc.gov/std/>

HIV / AIDS
<http://www.cdc.gov/hiv/>

Centre Européen Sida
<http://www.eurohiv.org/>

European Centre for Disease Prevention and Control (ECDC)
<http://www.ecdc.europa.eu/en/Pages/home.aspx>

European Centre for the Epidemiological Monitoring of AIDS
<http://www.eurohiv.org/>

The Global Fund to Fight AIDS, Tuberculosis and Malaria
<http://www.theglobalfund.org/en/>

Health Sciences Research Institute of the "Germans Trias i Pujol" Foundation (IGTP)
<http://www.germanstrias.org/>

Fundació Sida i Societat
<http://www.sidaisocietat.org/>

Foundation for the Research and Prevention of AIDS in Spain
<http://www.fipse.es/>

Generalitat de Catalunya. Health Department
<http://www.gencat.cat/salut/>

Working Group on HIV Treatment
<http://gtt-vih.org/>

Hospital Universitari Germans Trias i Pujol (HUGTiP)
<http://www.gencat.cat/ics/germanstrias/>

Infosida

<http://www.gencat.cat/salut/depsalut/html/ca/dir2138/index.html>

Joint United Nations Programme on HIV/AIDS. UNAIDS

<http://www.unaids.org/en/default.asp>

World Health Organization (WHO)

<http://www.who.int/es/>

Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

<http://www.seepidemiologia.es/>

Spanish Epidemiology Society (SEE)

<http://www.seepidemiologia.es/>

Spanish Interdisciplinary Society of AIDS (SEISIDA)

<http://www.seisida.net/>

XVII International AIDS Conference. Mexico City (Mexico); 2008 August 3-8.

<http://www.aids2008.org/>

XVIII International AIDS Conference. Vienna (Austria), 2010 July 18-23

<http://www.aids2010.org/>

II. Abbreviations list

ACAS	Community AIDS Association of Catalonia	DS	Health Department	IA	Induced abortion
ACASC	Citizens AIDS Association of Catalonia	EAP	Primary healthcare team	IDESCAT	Statistical Institute of Catalonia
AERI-VIH Project	Standardized Algorithm for Recent HIV Infections Study Group	EC	Emergency contraception	IDU	Injecting drug user
ART	Antiretroviral therapy	ECDC	European Centre for Disease Prevention and Control	IQR	Interquartile range
ASCUS	Atypical Squamous Cells of Undetermined Significance	ESHS	Health and Sexual Habits Survey	ITACA Project	Cohort of HIV negative MSM for the study of early HIV and STI diagnosis and their determining factors
ASPB	Barcelona Public Health Agency	EU	European Union	LGV	Lymphogranuloma Venereum
ASSIR	Sexual and reproductive health assistance	FIPSE	Foundation for the Research and Prevention of AIDS in Spain	LR-HPV	Low-risk Human Papillomavirus
AZT	Zidovudine	FSW	Female sex worker	LSIL	Low-grade squamous intraepithelial lesion
CAP	Primary healthcare centre	HAART	Highly active antiretroviral therapy	MDD	Mandatory declaration diseases
CAS	Health and social services centre	HCV	Hepatitis C virus	MSM	Men who have sex with men
CDC	Centers for Disease Control and Prevention	HIVDEVO Project	Monitoring of voluntary detection of HIV antibodies in NGO alternative diagnosis and assisted counseling centres	NENEXP Project	Clinical and Epidemiological Study on HIV and Antiretroviral Drugs Exposed Mothers and Children
CEEISCAT	Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia	HIVLABCAT Project	Declaration of all tests and new HIV infection diagnoses carried out in the laboratory network of Catalonia	NNRTI	Non-nucleoside reverse transcriptase inhibitor
CI	Confidence interval	HPV	Human Papillomavirus	NONOPEP Project	State epidemiological information system on non occupational post-HIV exposure prophylaxis
CJAS	Sexuality and Contraception Youth Centre	HR-HPV	High-risk Human Papillomavirus	NPEP	Non-occupational post exposure prophylaxis
CT/NG- Presons Project	Prevalence study of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> and its determinants among young people under 25 years old inmates in preventive prisons	HSIL	High-grade squamous intraepithelial lesion	NRTI	Nucleoside reverse transcriptase inhibitor
		HSV	Herpes simplex virus	OR	Odds ratio
		HUGTiP	Germans Trias i Pujol Hospital		

PCR	Polymerase chain reaction
PI	Protease inhibitor
PI/b	Boosted protease inhibitor
PISCIS Project	
	Project for the computation of the clinical-epidemiological monitoring of HIV infection and AIDS
RI	Recent infections
RITS	Register of STIs in Catalonia
RTV	Register of vertical transmission
SAPS	Prevention and treatment service for health and social care
SD	Standard deviation
SIALON Project	
	Capacity building in HIV/Syphilis prevalence estimation using non-invasive methods among MSM in Southern and Eastern Europe
SIVES	Integrated AIDS/HIV/STI Surveillance System of Catalonia
SNMC	Microbiological Notification System of Catalonia
SRH	Sexual and reproductive health
STARHS	Serological Testing Algorithm for Recent HIV Seroconversion
STI	Sexually transmitted infection
SW	Sex worker
UAI	Unprotected anal intercourse
UITS	Units of sexually transmitted infections

UVE	Epidemiological Surveillance Units
VL	Viral load
VT	Vertical transmission
WHO	World Health Organization

III. Tables list

Table 1.1.1. Country of origin of new HIV infection diagnoses. Catalonia, 2001-2008.

Table 1.1.2. AIDS cases diagnosed per million inhabitants. Spain, 2008.

Table 1.1.3. Number of AIDS cases that reside in Catalonia and incidence rate (per 100,000 inhabitants) by health region, 2000-2008.

Table 1.1.4. Distribution of AIDS defining conditions of cases that reside in Catalonia by periods, 1981-2008.

Table 1.1.5. Years of potential life lost (YPLL-65) attributable to AIDS mortality. Catalonia, 1992-2007.

Table 1.1.6. Rate of persons that survive more than 12, 24 and 36 months after AIDS diagnosis by certain characteristics, 2000-2002.

Table 1.2.1. Frequency and rates* of mandatory declaration STIs per year. Catalonia, 1996-2008.

Table 1.2.2. Frequency and rates* of notified cases of mandatory declaration STIs per year and health region. Catalonia, 2008.

Table 1.2.3. Yearly frequency of STIs notified to the SNMC, 1996-2008.

Table 1.2.4. Distribution of STIs notified to the SNMC by sex and age group, 2008.

Table 1.2.5. Number of notified STIs episodes by sex and sexual orientation. Register of STIs, 2007-2009.

Table 1.2.6. HIV+ status by sex and sexual orientation. Register of STIs, 2007-2009.

Table 1.2.7. Main characteristics of the RITS patients, ASSIR, 2007-2009 (N=281 patients).

Table 1.2.8. Main characteristics of the RITS patients, UITS, 2007-2009 (N=2191 patients).

Table 1.2.9. Main characteristics of the RITS patients, sentinel network doctors in Primary Assistance in Catalonia, 2007-2009 (N=64 patients).

Table 2.1.1. Summary of epidemiological surveillance of HIV infection in sentinel populations in Catalonia, 2007-2008.

Table 2.2.1. Prevalence of HIV infection in pregnant women (HIVNADO) in Catalonia, 2008.

Table 3.1.1. Sociodemographic and behaviour characteristics and HIV and STI prevalence in MSM interviewed through the internet.

Table 3.1.2. Sociodemographic characteristics and HIV testing. MSM, 1995-2008.

Table 3.1.3. Sexual behaviour. MSM 1995-2008.

Table 3.2.1. Sociodemographic characteristics and HIV and HCV testing in IDU.

Table 3.2.2. Drugs use characteristics and sexual behaviour (last 6 months) in IDU.

Table 3.2.3. HIV HCV *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in biological samples collect in IDU.

Table 3.3.1. Sociodemographic, sexual work, drug use and health status characteristics in female SW by country of origin.

Table 3.3.2. Comparison of main indicators collected in interviews to FSW

in Catalonia and HIV chlamydia and gonorrhoea prevalences by country of origin (2005-2007).

Table 4.1.1. Number of anti-HIV tests carried out per 1,000 inhabitants in European countries, 2008.

Table 4.2.1. Number of tests carried out, number of positive tests and positive rate. Diagnosis and assisted counselling centres of Catalonia, 2006-2008.

Table 4.2.2. Number of anti-HIV tests carried out and positive rate per kind of test. Diagnosis and assisted counselling centres of Catalonia 2007-2008.

Table 4.3.1. Coverage of the diagnostic test in certain special interest groups. Catalonia, 1993-2008.

Table 5.1.1. Distribution of notified cases by centre, 2001-2008.

Table 5.1.2. Distribution of notified exposure types.

Table 5.1.3. Distribution of treatments and patterns by exposure risk category.

Table 5.1.4. Causes of interrupted treatment in treated persons and one-month follow-up.

Table 5.1.5. Number and type of side effects in ART treated persons that come to a following visit.

Table 5.2.1. Description of patients at the time of inclusion. PISCIS cohort January 1998 - October 2009.

Table 5.2.2. Description of naive patients initiating treatment. PISCIS cohort, January 1998 - October 2009.

Table 5.3.1. Time of diagnosis of HIV infection in the mother.

Table 5.4.1. Characteristics of new HIV diagnoses, according to have been identified as RI.

Table 5.5.1. Epidemiological characteristics of patients with mutations associated to resistances.

Table 5.6.1. Distribution of HPV types.

Table 5.6.2. Main sociodemographic, behavioural, and clinical characteristics of the HIV and HPV co-infected women.

Table 5.6.3. Behavioural characteristics of women co-infected with HIV and HR-HPV.

Table 5.6.4. History of cervical cancer screening for women co infected with HIV and HR-HPV.

Table 5.6.5. Clinical characteristics of women co-infected with HIV and HR-HPV.

IV. Figures list

Figure 1.1.1. New HIV infection diagnoses per million inhabitants. WHO European Region, 2008.

Figure 1.1.2. Annual distribution of new HIV diagnoses per sex. Catalonia, 2001-2006.

Figure 1.1.3. Percent distribution of new HIV diagnoses by transmission group and sex. Catalonia, 2001-2008.

Figure 1.1.4. Evolution of new HIV diagnoses by transmission group. Catalonia, 2001-2008.

Figure 1.1.5. Evolution of new HIV diagnoses in immigrant population. Catalonia, 2001-2008.

Figure 1.1.6. New HIV diagnoses per country of origin, transmission group and sex. Catalonia, 2001-2008.

Figure 1.1.7. New HIV diagnoses in immigrants per geographical area, transmission group and sex. Catalonia, 2001-2008.

Figure 1.1.8. AIDS cases per sex and year of diagnosis. Catalonia, 1981-2008.

Figure 1.1.9. Percent evolution of AIDS cases by transmission groups and periods. Catalonia, 1981-2008.

Figure 1.1.10. Percent evolution of AIDS cases by transmission group and sex. Catalonia, 1981-2008.

Figure 1.1.11. Paediatric AIDS incidence by year of birth. Catalonia, 1986-2008.

Figure 1.1.12. AIDS cases living in Catalonia, 1981-2007.

Figure 1.1.13. New HIV infection by transmission group and sex in Barcelona, 2001-2008.

Figure 1.1.14. AIDS cases and new HIV diagnoses in Barcelona, 1988-2008.

Figure 1.2.1. STI rates per 100,000 inhabitants by autonomous community. Spain, 2008.

Figure 1.2.2. Sources of information of the new STI register.

Figure 1.2.3. STI rates per 100,000 inhab. Compulsory notification. Catalonia, 1996-2008.

Figure 1.2.4. STI rates per 100,000 inhabitants by regions of Catalonia. 2008.

Figure 1.2.5. Number of infectious syphilis, gonococchia and LGV by age-group and sex. 2008.

Figure 1.2.6. STI declared to the SNMC, 1996-2008.

Figure 1.2.7. STI declared to the SNMC by age-group and sex, 2008.

Figure 1.2.8. STI declared to the SNMC by sex, 2002-2008.

Figure 1.2.9. Selected STI by sexual orientation. 2007-2009.

Figure 1.2.10. Trends of Infectious syphilis, Gonococchia, Chlamydia and Trichomonas. Catalonia, 1996-2009.

Figure 1.2.11. Time trends of genital warts and herpes, 1996-2009.

Figure 2.1.1. HIV infected people amounts evolution. Catalonia, 1994-2008.

Figure 2.2.1. HIV infection prevalence evolution in Catalonia in several sentinel populations, 1990-2008.

Figure 2.2.2. Seroprevalence evolution per mother age groups, 1994-2004. (HIVNADO study).

Figure 2.2.3. Seroprevalence evolution per mothers' country of origin, 2002-2008. (HIVNADO study).

Figure 2.2.4. HIV prevalence evolution in sentinel populations, high risk population. Catalonia, 1993-2008.

Figure 2.3.1. *Chlamydia trachomatis* and *Neisseria gonorrhoeae* prevalence in urine samples, recruited in harm reduction centres.

Figure 2.3.2. *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in FSW, Catalonia (2005-2007).

Figure 3.1.1. Condom use frequency in anal sex with steady and occasional partners. MSM, 1995-2008.

Figure 3.1.2. Drugs use prevalence before or during sexual intercourse. MSM 1995-2008.

Figure 3.1.3. STI diagnosed last 12 months. MSM, 1995-2008.

Figure 3.2.1. Prevalence of sharing injection of intravenous drugs material in IDU (last 6 months).

Figure 3.2.2. Prevalence of consistent condom use with steady partners in IDU (last 6 months).

Figure 3.3.1. Prevalence of consistent condom use by type of partner in FSW (last 6 months).

Figure 3.3.2. Prevalence of HIV Chlamydia trachomatis and Neisseria gonorrhoea in FSW (2007).

Figure 4.1. Information sources on HIV diagnosis tests in Catalonia.

Figure 4.1.1. Estimation of the rate of diagnosis tests per sanitary region. Catalonia, 2008.

Figure 4.1.2. Number of HIV diagnosis tests carried out and rate of positive results. Catalonia laboratories network, 1993-2008.

Figure 4.1.3. HIV positive tests rate per sex and age group. Catalonia laboratories network, 1997-2008.

Figure 4.2.1. Number of anti-HIV tests carried out and positives rate. Diagnosis and assisted counselling centres of Catalonia, 1995-2008.

Figure 4.2.2. Percent of HIV diagnosis tests reported and percent of positives. Distribution per age and sex. Diagnosis and assisted counselling centres of Catalonia, 1995-2008.

Figure 4.2.3. Changes in the distribution of tests and positive tests by risk group, 1995-2008.

Figure 4.2.4. Annual evolution of the percentage of positive tests by risk group, 1995-2008.

Figure 4.4.1. Percentage of AIDS cases with late diagnosis per transmission group and period. Catalonia, 1981-2004.

Figure 4.4.2. Characteristics late diagnosis in new cases of HIV infection. Catalonia, 2001-2008.

Figure 4.4.3. Changes in late diagnosis in new HIV infection diagnoses. Catalonia, 2001-2008.

Figure 4.4.4. Characteristics of late diagnoses in new cases of HIV infection in PISCIS cohort, period 1998-2009.

Figure 4.4.5. Changes in late diagnosis in new HIV infection diagnoses. Catalonia, 2001-2008.

Figure 5.2.1. PHIV infection progression. PISCIS cohort, 1998-2009.

Figure 5.2.2. Annual evolution of the regimen of starting ART in naive patients. PISCIS cohort (1998-2009).

Figure 5.3.1. VT rate evolution in Catalonia, NENEXP Project 2000-2009.

Figure 5.3.2. Evolution of the mode of delivery in HIV-positive mothers newborns. Project NENEXP, 2000-2009.

Figure 5.4.1. Algorithm for the identification of samples with RI.

Figure 5.4.2. RI percentage by sex.

Figure 5.4.3. RI percentage by origin.

Figure 5.4.4. RI percentage by age group.

Figure 5.4.5. RI percentage by transmission group.

Figure 5.4.6. RI percentage by STI diagnosis in the last 12 months.

Figure 5.5.1. Transmitted resistances by origin.

Figure 5.5.2. Transmitted resistances by HIV-1 subtype.

Figure 5.5.3. Number of mutations associated to resistances by drug family.

Figure 5.5.4. Distribution of HIV-1 subtypes, by age group.

Figure 5.5.5. Distribution of HIV-1 subtypes, by transmission group.

Figure 5.5.6. Distribution of HIV-1 subtypes, by origin.

Figure 5.6.1. Algorithm for detection of HPV infection and cervical lesions in HIV positive women participating in the study.

Figure 5.6.2. Cervical lesions prevalence of the HIV positive women participating in the study.

V. Images list

Image 1.1. HIV Transmission patterns have changed over the years and nowadays HIV transmission is mainly by sexual practice. Promoting safe sex is an important primary health prevention intervention.

Image 1.2. Continuous professional development improves abilities for prevention and early detection of HIV and other STI.

Image 2.1. Preventive interventions to IDUs should adapt to their social and cultural context.

Image 3.1. New technologies are spreading quickly in our society and the internet is becoming as a new mean targeting prevention interventions, especially in MSM.

Image 3.2. Female SW are one of vulnerable groups to HIV and other STI infections. Improve targeting education and information about reproductive and sexual health will be important in order to help avoiding those infections in this group.

Image 4.1. Late diagnosis observed among new diagnoses of HIV infection remains high. It is necessary to continue promoting early diagnosis of HIV in general population and especially in vulnerable groups with high prevalence of HIV infection.

Image 5.1. Rapid tests for detection of antibodies against HIV.

Image 5.2. The highest percentage of RI is observed among MSM. Continuing to promote HIV testing in this group is essential.

VI. Contributors from the diverse information systems

AIDS/HIV/STIs epidemiological surveillance

Public Health Emergencies Survey and Response General Subdirectorate

Public Health General Directorate (J.M. Jansà, Pere Godoy, G. Carmona, M. Oviedo, P. Ciruela, S. Hernández).

Epidemiological Surveillance Units

UVE Regió Barcelonès Nord i Maresme (J. Álvarez); UVE Regió Costa de Ponent (I. Barrabeig); UVE Regió Centre (R. Sala); UVE Regió Catalunya Central (R. Torra); Girona territorial health services (N. Camps, M. Company); Lleida territorial health services (P. Godoy); Tarragona territorial health services (S. Minguell); Terres de l'Ebre territorial health services (G. Ferrus); ASPB (J.A. Caylà, P. Garcia de Olalla, R. Clos); Penitentiary, Rehabilitation and Youth Justice Services. Health and Rehabilitation Programs Subdirectorate. Justice Department (R.I. Guerrero, V. Humet).

Mortality data

Register of mortality. Information and Studies Service. Health Resources General Directorate. DS (R. Gispert, A. Puigdefàbregas, G. Ribas).

Reference laboratories

Microbiology service. HUGTIP (V. Ausina, V. González, L. Matas, E. Martró, D. Sánchez).

HIVNADO

Neonatal Screening Unit. IBCCDB. Corporació Sanitària Clínic (J.L. Marin, A. Maya, M. Puliol, F. Borja, C. Martínez).

HIVIVES

Neonatal Screening Unit. IBCCDB. Corporació Sanitària Clínic (J.L. Marin, A. Maya, M. Puliol, F. Borja, C. Martínez); Information and Studies Service. Health Resources General Directorate. DS (R. Gispert, J.J. Coll, R. Bosser, M.M. Torne, M. Femenias); Clínica d'Ara-Tutor Mèdica (S. Barambio, J. Fernandez, R.M. Boj, Y. Trejo); Clínica E.M.E.C.E. (M. Sánchez); Centro Casanova de Ginecología y Planificación, S.A. (R. Novo, M. Palma).

HIVLABOR

Dr. Echevarne laboratory (J. Huguet, I. Fernandez).

HIVUDVP

Drug Addiction Technical Unit. Public Health General Directorate. DS (J.M. Suelves, X. Ayneto).

HIVPRESO

Penitentiary, Rehabilitation and Youth Justice Services Secretary's Office. Health and Rehabilitation Programs General Subdirectorate. Justice Department (R. Guerrero, M.V. Humet); Serveis Perifèrics (A. Puertolas, D. Estallo, M. Lonca).

SIALON

This study belongs to the project "Capacity building in HIV/Syphilis prevalence estimation using non-invasive methods among MSM in Southern and Eastern Europe". Partners: Czech Republic, Greece, Italy, Romania, Slovakia, Slovenia, Spain and EU/DGSANCO, European Commission under the Public Health Programme 2003-2008.

Catalan partners: Microbiology Service. HUGTIP; Associació Stop Sida (K. Zaragoza, R. Muñoz, P. Fernández and interviewers: Blai, Jano, Lluís, Miquel).

REDAN

Associació Àmbit Prevenció (M. Meroño, A. Altabas); ASPB (T. Brugal, A. Espelt, C. Vecino); Drug Adiction Office. General Directorate. DS (X. Majó, J. Colom); Microbiology service. HUGTIP (V. González, E. Bascuñana, V. Ausina); other harm reduction centres (SAPS, Baluard, health and social services centre (CAS, according to the Catalan acronym) Vall d'Hebron; "El Local" de Sant Adrià; AEC-Gris; Asaupam Santa Coloma; CAS Reus, AIDE Terrassa, Alba Terrassa, Arrels Lleida; Mercè Fontanilles Lleida; Creu Roja, Constantí; IAS Girona) and interviewers (C. Stanescu, C. Daigre, P. Freixa, A. Mestres, S.I. Moreira, F. Bocali, P. Sánchez, R. Kistmacher, K. Cornejo, S. Riveros, E. Lafita, M. Muñoz, M. Pardell, J. Obiols, C. Escué).

HIVITS-TS

Associació Àmbit Prevenció (C. Sanch Clemente, C. Lazar i entrevistadores:

C. Jaques, C. Lazar, A. Stoicescu, M. Bessa, M. Castro, S. Lopez, S. Fernández, C. Rives, D. Faixó, A. Rafel, M.P. Aedo, B. Alsina, C. Benítez) and the associations: Antisida de Lleida, Mercè Fontanilles, Programa Carretera (Hospital Sant Jaume de Calella), ACAS de Girona, Actua Vallès i Creu Roja, Tarragona.

HIVUDVPT

Drug Adiction Office. Public Health General Directorate. DS (J.M. Suelves, X. Ayneto).

RITS: Register of STIs in Catalonia

Sexual Units of sexually transmitted infections

Primary healthcare centre (CAP, according to the Catalan acronym) CAP Les Drassanes. Barcelona (M.J. Barberà, A. Vives, B. Sanz, P. Armengol, M. Vall, M.J. Villena, E. Arellano, P. Saladier, M. Arando); CAP Tarragonès. Tarragona (J. Boronat, R. Soriano).

Catalonia STIs Sentinel Network

CAP Fondo. Santa Coloma de Gramenet (E. Martin, S. Rodoreda); CAP Sant Martí. Barcelona (B. Escorihuela); CAP Can Bou. Castelldefels (M. Urbano); CAP El Remei. Vic (P. Aguilà, R. Codinach); CAP Santa Tecla-Llevant. Tarragona (J. Montoya, S. Borrás, M.C. Nolla); CAP Larrard. Barcelona (F. Díaz, A. Santiveri, J.M. Casermeiro, S. Barro, M.C. Prado); CAP Salt (M.D. Rivero); CAP Baix Ebre. Tortosa (G. Batlle); CAP Salou (M.C. Rubio); CAP Puigcerdà (B. Fontecha); CAP Sardenya. Barcelona (J. Sellarès, A. Casasa); CAP Doctor Carles Ribas. Barcelona (M.A. De la Poza); CAP La Florida. L'Hospitalet de Llobregat (R. Carrillo, J. Mascort); CAP La Mina. Barcelona (J.M. Mendives, M. Garcia, J.M. Baena); CAP Sant Fruitós de Bages (X. Puigdemongas); CAP Vila Seca (A. Fallada); CAP Josep Torner i Fors. Malgrat de Mar (M. Tejedor);

CAP Arenys de Mar (R. Hueso); CAP Premià de Mar (A. Valls); CAP Baix-a-Mar. Vilanova i la Geltrú (G. Torrell, J. Milozzi); CAP Calella (S. Curós); CAP Gornal. L'Hospitalet de Llobregat (C. Pérez); CAP Mataró 1 (P. Paulo); EAP Guillem Masriera. Vilassar de Mar (C. Viñas, J. Gerhard); EAP-5 Santa Rosa. Santa Coloma de Gramenet (S. Montesinos); Barcelona and Maresme International Health Unit. Santa Coloma de Gramenet (L. Valerio).

Health professionals of the sexual and reproductive assistance programs

ASSIR groups

City of Barcelona:

ASSIR CAP Carles Ribas, CAP Manso, CAP Numància, CAP Vila Olímpica, CAP Clot (C. Martínez, E. Vela, R. Almirall, J. Xandri, A. Díez, A. Rodas, N. Domínguez, C. Seguí, O. Eddy, S. Bozal, A. Payaro, L. Caccioppoli, E. Grau, J. Cid, E. Laso, M. Honrrado); EAP Raval Nord (M. Vilamala, S. Haimovich, A. Ramírez); CJAS (R. Ros, I. Campo).

Metropolitan area:

ASSIR CAP Sant Fèlix. Sabadell (G. Falguera, L. Grado, Sola); ASSIR CAP Mare de Déu de Lorda. Badalona (A. AVECILLA, M. de Sebastián, M. Teixido); ASSIR Maresme. Mataró (C. Coll, Castro).

Tarragonès:

ASSIR CAP Tarragonès. Tarragona (J. Boronat).

Central Catalonia:

ASSIR Cerdanyola Ripollet (P. Soteras, A. Acera, C. Basset, R. Contero, F. Casas, J. Jiménez, I. Rosa, D. Rodríguez, M. Llucià); ASSIR CAP II Granollers (D. Guix, J. Relat, F. Abella, R. Hernández, M. Vila, C. Serra, S. Corchs); ASSIR CAP Osona (J. Grau Galtés, A. Masoliver Jordana, R. Subirats Alberich); ASSIR CAP Bages (R. Forn Guilanyà, R. Oller Bellmunt, C. Ramos Ratrero, M. Vendrell Brià); AS-

SIR Hospital d'Igualada (T. Garcia, J. Rovira, Z. Colman); ASSIR CAP Berguedà (A. Benavidez, C. Comellas, C. Rincón); ASSIR CAP II Plana Lledó (M. Casajoana, M. Manzanarez); ASSIR Mútua de Terrassa (O. Ezquerro, G. Coll, X. Urquizu); ASSIR CAP II Mollet del Vallès (E. López, M. Ayuso).

Primary healthcare laboratories

L'Hospitalet clinical laboratory (E. Dopico, E. Greznzer); Maresme clinical laboratory (P. Planells, P. Felipe); Bon Pastor clinical laboratory (R. Lopez, R. Juve, P. Felipe); Manso clinical laboratory (A. Tirado, J. Bove); Alt Penedès, l'Anoia i el Garraf laboratory consortium (F. Corcoy, R. Angrill, M.A. Benítez).

CT/NG/VPH-PRESONS

Wad Ras prison (V. Humet, L. Barbero, J. Rodriguez); La Trinitat prison (V. Humet, G. Almada, M.J. Leal, N. Llopart, E. Torrez, M.A. Garcia).

Monitoring HIV prevention and behavior

SIALON

This study belongs to the project "Capacity building in HIV/Syphilis prevalence estimation using non-invasive methods among MSM in Southern and Eastern Europe". Partners: Czech Republic, Greece, Italy, Romania, Slovakia, Slovenia, Spain and EU/DGSANCO, European Commission under the Public Health Programme 2003-2008.

Catalan partners: Microbiology service. HUGTiP; Associació Stop Sida (K. Zaragoza, R. Muñoz, P. Fernández and interviewers: Blai, Jano, Lluís, Miquel).

REDAN

Associació Àmbit Prevenció (M. Me-roño, A. Altabas); ASPB (T. Brugal,

A. Espelt, C. Vecino); Drug Adiction Office. Public Health General Directorate. DS (X. Majó, J. Colom); Microbiology service. HUGTIP (V. González, E. Bascuñana, V. Ausina); other harm reduction centers (SAPS, Baluard, CAS Vall d'Hebron; "El Local" Sant Adrià; AEC-Gris; Asaup'am Santa Coloma; CAS Reus, AIDE Terrassa, Alba Terrassa, Arrels Lleida; Mercè Fontanilles Lleida; Creu Roja, Constantí; IAS Girona) and interviewers (C. Stanescu, C. Daigre, P. Freixa, A. Mestres, S.I. Moreira, F. Boccali, P. Sánchez, R. Kistmacher, K. Cornejo, S. Riveros, E. Lafita, M. Muñoz, M. Pardell, J. Obiols, C. Escué).

HIVITS-TS

Associació Àmbit Prevenció (C. Sanclemente, C. Lazar and interviewers: C. Jaques, C. Lazar, A. Stoicescu, M. Bessa, M. Castro, S. Lopez, S. Fernández, C. Rives, D. Faixó, A. Rafel, M.P. Aedo, B. Alsina, C. Benítez) and the associations: Associació Antisida de Lleida, Mercè Fontanilles, Programa Carretera (Hospital Sant Jaume de Cal·lella - Corporació de Salut del Maresme i La Selva), ACAS Girona, Actua Vallès i Creu Roja, Tarragona.

Monitoring HIV diagnosis

Catalonia laboratories (HIVLABCAT)

Clinical testing service. Hospital Universitari Arnau de Vilanova (J. Farré); Tarraco clinical laboratory (A. Vilanova, L. Guasp, C. Sarvisé); Clinical laborator. CAP Just Oliveres, L'Hospitalet (E. Dopico); Cornellà clinical laboratory (R. Navarro); El Maresme clinical laboratory (C. Vilanova); Barcelonès Nord i Vallès Oriental clinical laboratory (J. Ros, C. Guar-

dià); Bon Pastor clinical laboratory (R. López); Manso clinical laboratory (I. Rodrigo); Alt Penedès, l'Anoia i el Garraf laboratory consortium (A. Bosch, M.A. Benítez); Microbiology service. Hospital Universitari de Sant Joan de Reus (J. Joven); Servei d'Hematologia. Hospital de Tortosa Verge de la Cinta (X. Ortin); Clinical laboratory. Hospital Universitari de Girona Dr. Josep Trueta (M.J. Ferri); Hospital Santa Caterina (M.L. Urcola); Clinical testing service. Hospital Sant Jaume de Calella (I. Caballé, J. Massa); Microbiology service. Hospital de Mataró (G. Sauca); Microbiology service. HUGTIP (L. Matas); Microbiology laboratory. Hospital Universitari de Bellvitge (A. Casanova); Clinical laboratory. Hospital General de l'Hospitalet (D. Dot, E. Márquez); Microbiology laboratory. Fundació Hospital Sant Joan de Déu de Martorell (M.A. Gasos); Biochemistry service. Hospital General de Granollers (M.C. Villa); Microbiology laboratory. Hospital General de Vic (J.M. Eurás); Hospital General de Manresa (J. Franquesa); Hospital de Sant Joan de Déu de Manresa (M. Morta); Immunology laboratory. Corporació Sanitària Parc Taulí (M.J. Amengual); Microbiology laboratory. Hospital de la Santa Creu i Sant Pau (N. Margall); Microbiology laboratory. Hospital Clínic i Provincial de Barcelona (T. Pumarola, J. Costa); Microbiology laboratory. Catalonia referente laboratory (M. Salvador); Microbiology service. Hospital Universitari Vall d'Hebron (E. Caballero); Dr. Echevarne laboratory (J. Huguet).

Diagnosis and assisted counseling centers of Catalonia (HIVDEVO)

CJAS (R. Ros, A.M. Gutiérrez; M. Pérez); SAPS (E. Juárez, O. Díaz, E. Adan); Stop-Sida (K. Zaragoza, B. Gil); Associació Anti-Sida de Lleida (N. Barberà, A. Binaixa, A. Rafel);

ACASC (E. Caballero, J. Becerra, L.A. Leal); Actua Vallès (A. Avellaneda, M. Sité, B. Alsina); Projecte dels Noms (J. Saz, F. Pujol, M. Meulbroeck); Associació Àmbit Prevenció (M. Meroño, C. Jacques, C. Lazar, S. Silva); Gais Positius (V. Mateu, J. Roquetam R. Araneda); ACAS Girona (A. Lara).

COBEMB

Hospital Clínic i Maternitat, Barcelona (R. Ros, V. Cararach, S. Pisa); Hospital de Sant Joan de Déu (J.M. Lailla, I. Bombi, E. Gómez); HUGTIP (O. Gamisans, A. Asensio, M. Luna); Hospital de Terrassa (J. Sáez, M. Aznar, C. Rigau); Corporació Sanitària Parc Taulí (C. Foradada, C. Grau, S. Moros); Hospital Universitari Joan XXIII de Tarragona (R.M. Miralles, E. Aguilar, E. Segura); Hospital Universitari Arnau de Vilanova (M. Muñoz, E. de Diego, A. González); Hospital Universitari de Girona Dr. Josep Trueta (J. Sabria, A. Montells); Hospital de Barcelona (C. Humet, C. Vila); Institut Universitari Dexeus (J. Mallafre, A. Suris, X. Murciano).

Other projects

PISCIS Cohort

Hospital Clínic - IDIBAPS (J.M. Miró, J.M. Gatell, F. Agüero, I. Pérez, M. Sanchez, J.L. Blanco, F. Garcia-Alcáide, E. Martínez, J. Mallolas, M. López-Dieguez, J.F. García-Gozé); Hospital Universitari de Bellvitge (D. Podzamczar, E. Ferrer, M. Olmo, P. Barragan, M. Saumoy, F. Bolao, C. Cabellos, C. Peña); Hospital Universitari Son Dureta (J. Murillas, M. Riera); HUGTIP (C. Tural, B. Clotet, G. Sirera, J. Romeu, A. Jou, E. Negredo, C. Miranda, M.C. Capitán); Corporació Sanitària Parc Taulí (F. Segura, G. Navarro, M. Sala, M. Cervantes, M.J. Amengual, M. Navarro, E. Penelo); Hospital de

Mataró (L. Force, P. Barrufet); Hospital General de Vic (J. Vilaró); Hospital de Palamós (A. Masabeu); Hospital General de L'Hospitalet (I. García); Hospital Comarcal de l'Alt Penedès (M. Guadarrama).

AERIVIH

Laboratories

Manso clinical laboratory. Barcelona (I. Rodrigo); Intercomarcal de l'Alt Penedès, l'Anoia i el Garraf laboratory consortium (M.Á. Benítez, A. Cebollero); Hospital Clínic - IDIBAPS (T. Pumarola); Hospital Universitari de Bellvitge - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) (A. Casanova); HUGTIP (E. Martró, L. Matas, V. González, V. Ausina); Hospital Universitari Vall d'Hebron (E. Caballero); Hospital de la Santa Creu i Sant Pau (N. Margall); Hospital Universitari Arnau de Vilanova (J. Farré); Hospital de Mataró (M.G. Saucá); Hospital de Tortosa Verge de la Cinta (X. Ortín); Corporació Sanitària Parc Taulí (M.J. Armengual); Hospital de Palamós (J.M. Prats); Hospital General de Vic (M. Navarro); Hospital Universitari de Sant Joan de Reus (J.M. Simó); Hospital General de l'Hospitalet (E. Márquez).

Clinicals

Hospital Clínic - IDIBAPS (J.M. Miró, F. Agüero, O. Sued, M. López-Diéguez, C. Manzardo, J.M. Gatell); Hospital Universitari de Bellvitge - IDIBELL (E. Ferrer, D. Podzamczzer); HUGTIP (C. Tural, B. Clotet); Hospital Universitari Vall d'Hebron (E. Ribera); Hospital Comarcal de l'Alt Penedès (J.M. Guadarrama); Hospital de la Santa Creu i Sant Pau (P. Domingo, M.M. Gutiérrez, M.G. Mateu, J. Martínez); Hospital Universitari Arnau de Vilanova (T. Puig); Hospital de Mataró (P. Barrufet, L. Force); Hospital de Tortosa Verge de la Cinta (A. Ortí); Corporació Sanitària Parc Taulí (G. Navarro, F. Segura); Hospital de Palamós (A. Masabeu);

Hospital Universitari de Sant Joan de Reus (B. Coll, C. Alonso Villaverde); Hospital General de l'Hospitalet (I. García).

Community-based testing sites

Sabater Tobella laboratory (R. Sala); SAPS - Creu Roja, Barcelona (O. Díaz, E. Adan); Associació Stop Sida (K. Zaragoza, B. Gil); Projecte dels Noms - Joves positius, Barcelona (F. Pujol, J. Saz, M. Meulbroek); Associació Àmbit Prevenició, Barcelona (M. Meroño, S. Silva, C. Lazar); ACASC (J. Becerra, L. Leal); CJAS (R. Ros, A. Gutiérrez, M. Pérez); Actua Vallès (B. Alsina, A. Avellaneda, M. Sité); Gais Positius (J. Roqueta, V. Mateu, R. Araneda).

Primary resistances to ARV and subtype determination in recent infections (AERIVIH subproject)

Hospital Clínic i Provincial de Barcelona (J.M. Miró, O. Sued, T. Pumarola, E. de Lazzari); Fundació IrsiCaixa (B. Clotet, L. Ruiz, T. Puig).

Laboratories

Manso clinical laboratory (I. Rodrigo); Cornellà de Llobregat clinical laboratory (R. Navarro); El Maresme clinical laboratory (C. Rovira); Hospital Universitari de Bellvitge - IDIBELL (A. Casanova); Microbiology service. HUGTIP (E. Martró, L. Matas, V. González, V. Ausina); Hospital Universitari Vall d'Hebron (E. Caballero); Hospital de la Santa Creu i Sant Pau (N. Margall); Hospital Universitari Arnau de Vilanova (J. Farre); Hospital de Mataró (M.G. Saucá); Hospital de Tortosa Verge de la Cinta (X. Ortín); Corporació Sanitària Parc taulí (M.J. Armengual); Hospital de Palamós (J.M. Prats); Hospital General de Vic (J.M. Euras); Hospital Universitari de Sant Joan de Reus (J.M. Simó); Hospital General de Granollers (M.C. Villa).

Clinicals

Hospital Clínic-IDIBAPS (F. Agüero, M. López-Diéguez, J.M. Gatell); Hospital Universitari de Bellvitge - IDIBELL (E. Ferrer, D. Podzamczzer); HUGTIP (C. Tural); Hospital Universitari Vall d'Hebron (E. Ribera); Hospital de la Santa Creu i Sant Pau (P. Domingo); Hospital Universitari Arnau de Vilanova (T. Puig); Hospital de Mataró (P. Barrufet, L. Force); Hospital Ramon y Cajal, Madrid (C. Gutiérrez); Hospital de Tortosa Verge de la Cinta (A. Ortí); Corporació Sanitària Parc Taulí (G. Navarro, F. Segura); Hospital de Palamós (A. Masabeu); Hospital Universitari de Sant Joan de Reus (B. Coll, C. Alonso Villaverde); Hospital General de Granollers (S. Montull).

Alternative screening centres

Sabater Tobella laboratory (R. Sala); Projecte dels Noms - Joves positius (F. Pujol, J. Saz), CJAS (R. Ros).

NONOPEP

Hospital Clínic i Provincial de Barcelona (F. Garcia, A. León); Hospital del Mar (A. Guelar); Hospital Universitari de Bellvitge (J.M. Ramon, C. Micheo); Hospital Universitari Vall d'Hebron (M. Campins, J.A. Rodriguez); Hospital Universitari Arnau de Vilanova (E. Barbe); Hospital General de Terrassa (F. Bella); Hospital de Tortosa Verge de la Cinta (A. Ortí).

HPV-PISCIS

Reference laboratory. Institut Català d'Oncologia (S. de Sanjosé, B. Lloveras, M. Oliveras, J. Godínez, J.E. Klaus-termeier); Hospital Clínic - IDIBAPS (J.M. Miró, M. Loncà, M. López-Diéguez, A. Torné, M. Sánchez, M. Redondo); Hospital Universitari de Bellvitge (D. Podzamczzer, E. Ferrer, D. Martí Cardona, E. Fernández); HUGTIP (C. Tural, G. Sirera, A. Tarrats, C. Alcalde); Corporació Sanitària Parc Taulí

(F. Segura, G. Navarro, M. Navarro, Y. Canet); Hospital de Mataró (L. Force, J. Solé); Hospital de Palamós (A. Masabeu, J.M. Marqueta); Hospital General de l'Hospitalet (I. Garcia, J. Mohamed Yahadih, N Pons, C Oses); Hospital Alt Penedès de Vilafranca (M. Guadarrama, I. Cuenca); Hospital de la Santa Creu i Sant Pau (P. Domingo, M.A. Sambeat, C. Vanrell, M. Macià).

NENEXP

Consorci Sanitari Clínic - Sant Joan de Déu (C. Fortuny, J.M. Pérez, J.M. Boguna, A. Noguera); Hospital Universitari Vall d'Hebron (M.C. Figueras, M. Casellas, P. Soler, A. Martin); Hospital del Mar. Barcelona (A. Mur, A. Paya); HUGTIP (C. Rodrigo, M. Mendez, N. Grane); Hospital General de Granollers (M.T. Coll); Corporació Sanitària Parc Taulí (V. Pineda); Hospital de Mataró (L. Garcia); Hospital Universitari Arnau de Vilanova (M.T. Vallmanya, T. Puig); Hospital Universitari Joan XXIII de Tarragona (A. Soriano, C. Bras, S. Veloso); Hospital Universitari de Sant Joan de Reus (F. Pagone); Universitat Ramon Llull (E. Sánchez), Research Support Services Costa de Ponent (J. Almeda).

ÍTACA

Hispanosida (F. Pujol, M. Meulbroek, H. Taboada, J. Saz, R. Fuertes/E. Diezel, C. Manzardo, J. Montilla); Empresa Q-Soft; data entry (A. Alsina).

And many other health professionals thanks to whose help and dedication the data presented here could be obtained.